Valneva Se · EURONEXT:VLA
Valneva — Investor Presentation (March 2026)
25 slides from Valneva's investor presentation, March 2026
Slide 1: A Leading Specialty Vaccine Company
A Leading Specialty Vaccine Company March 2026
Slide 2: Disclaimer
Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an offer Certain information and statements included in this presentation are not historical facts to buy or subscribe for, Valneva SE shares to any person in the USA or in any jurisdiction to but are for
Slide 3: A Leading Specialty Vaccine Company: Focused on vaccines that make a difference
Cash-Generating Specialty Vaccines Business: Proprietary travel vaccines: IXIARO®, DUKORAL®, IXCHIQ® A Leading Specialty Vaccine Company: Blockbuster Clinical Catalyst: Focused on vaccines that VLA15 (Lyme disease) partnered with Pfizer; significant unmet need with make a difference Phase 3 readout
Slide 4: Our Strategy as a Leading Vaccine Biotech Company
Our Strategy as a Leading Vaccine Biotech Company Contributing to a world in which no one dies or suffers from a vaccine preventable disease Fully Leverage … Maximize Integrated Biotech Drive R&D Upside Model Commercial Growth Augment clinical pipeline to achieve Create value with proven R&D Provide
Slide 5: Proprietary Commercial Portfolio of Differentiated Vaccines
Proprietary Commercial Portfolio of Differentiated Vaccines Differentiated vaccines Brand Indication Differentiation Key Markets Valneva direct markets: US, CA, UK, Only vaccine approved in U.S./Europe FR, Nordics, BE, NL, AT Active immunization against Japanese Requirement for U.S. military encepha
Slide 6: Vaccine Sales Fuel Strategic Investments into R&D
Vaccine Sales Fuel Strategic Investments into R&D Expect growth of proprietary brands; continued wind-down of third-party sales (3PP) to < 5% in 2026 163 Lean and Efficient 158 145 - 1601 Commercial Infrastructure IXCHIQ® 145 Highly experienced teams Deep vaccine expertise 115 Footprint extended thr
Slide 7: Valneva’s R&D Portfolio
Valneva’s R&D Portfolio Accelerating early development programs toward clinical entry post-Lyme1 Program Design/Description Pre-Clinical Phase 1 Phase 2 Phase 3 World’s most clinically advanced VLA15: Lyme vaccine candidate; protein Lyme disease subunit-based Clinical VLA1553: Post-marketing efficac
Slide 8: VLA15 World’s leading Lyme Disease Vaccine Candidate
VLA15 World’s leading Lyme Disease Vaccine Candidate
Slide 9: Lyme Disease Represents A Major Medical Need And Market Opportunity
Lyme Disease Represents A Major Medical Need And Market Opportunity No vaccine is currently available to prevent Lyme disease in humans Commercial opportunity for Valneva Annual Burden of Disease U.S. : ~476K cases Europe : >132K cases Severe Manifestations3 10-30% cases develop • Lyme carditis • Ly
Slide 10: World’s Leading Vaccine Candidate Against Lyme Disease
World’s Leading Vaccine Candidate Against Lyme Disease VLA15: the only Lyme disease program in advanced clinical development today Vaccine Market Key Highlights Opportunity Milestones Multivalent, recombinant proteins Exclusive, worldwide On track for Phase 3 data partnership2 readout in H1 2026; Re
Slide 11: VLA15 Demonstrated Strong Immunogenicity Across 1,030 Adults and Children
VLA15 Demonstrated Strong Immunogenicity Across 1,030 Adults and Children Three Phase 2 studies1 optimized dose and schedule across age groups 2020 2021 2022 First positive First positive First positive immunogenicity data booster data pediatric data VLA15-201 VLA15-202 VLA15-221 • Immunogenic (all
Slide 12: Phase 3: Vaccination Completed; First Data Readout Upcoming
Phase 3: Vaccination Completed; First Data Readout Upcoming Pfizer aims to submit regulatory applications in U.S. and Europe in 20261 Tick Season 2023 Tick Season 2024 Tick Season 2025 VLA15 Cohort 1 Placebo Month 0 2 5-9 6-10 13 18 19 25 Primary series Booster VLA15 Efficacy Cohort 2 Read-out Place
Slide 13: VLA15 is a Compelling Opportunity in an Underserved Market
VLA15 is a Compelling Opportunity in an Underserved Market First-Mover Differentiated Compelling Strategic Fit Attractive Advantage in Highly Yet De-Risked Target Population with Pfizer’s Vaccine Commercial Receptive Market Product Profile and Use Case Franchise Dynamics Only Lyme disease Proven MoA
Slide 14: IXCHIQ® / VLA1553 A Highly Differentiated single-shot Chikungunya Vaccine
IXCHIQ® / VLA1553 A Highly Differentiated single-shot Chikungunya Vaccine
Slide 15: Chikungunya: A Major Public Health Threat
Chikungunya: A Major Public Health Threat Mosquito-transmitted outbreak disease with potentially debilitating consequences • Often causes large, explosive outbreaks • Affecting up to 75% of the local population1 • Substantial quality-of-life and health-economic impact2 • Nearly half (43%) of those i
Slide 16: IXCHIQ®: A Highly Differentiated single-shot Chikungunya Vaccine
IXCHIQ®: A Highly Differentiated single-shot Chikungunya Vaccine Vaccine Market Key Highlights Opportunity Milestones Live-attenuated: offers strong and Travelers Potential upcoming approval of long-lasting protection with a locally developed vaccine single shot Military VLA-1555 in Brazil Approved
Slide 17: IXCHIQ®: Focused on Confirming Efficacy/Safety and Expanding Global Access
IXCHIQ®: Focused on Confirming Efficacy/Safety and Expanding Global Access Robust clinical program supported by CEPI grant Pilot Vaccination Campaign Ongoing (Brazil) To serve as the basis for post-marketing commitment studies • Launched in February 2026 with partner Instituto Butantan in select mun
Slide 18: S4V2 World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
S4V2 World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
Slide 19: S4V2: Opportunity to Develop First-in-Class Vaccine for a Life-Threatening Disease
S4V2: Opportunity to Develop First-in-Class Vaccine for a Life-Threatening Disease Tetravalent bioconjugate vaccine with potential to cover up to ~85% of shigellosis infections1 Vaccine Market Key Highlights Opportunity Milestones World’s most clinically advanced Global market expected to exceed Pha
Slide 20: Commercial Assessment of Shigella vaccine
Commercial Assessment of Shigella vaccine Shigella vaccine market estimated to peak at ~€500 million1 Children in endemic Traveler (~23%) Military (<1%) countries (~76%) 20-50% 30-100% 70-90% Recommendation (OOP-reimbursement) (Med-high risk destinations) (Med-high risk destinations Acceptance 30% 1
Slide 21: Financial Guidance & Outlook
Financial Guidance & Outlook
Slide 22: Valneva Remains Solidly Funded with Strong Financial Outlook
Valneva Remains Solidly Funded with Strong Financial Outlook 2026 Guidance Financial Outlook Product Sales: €145 - €160 million1; Commercial Continued revenue growth and cash flows from business expected to remain cash-flow positive commercialized vaccines Focused and strategic investments in R&D To
Slide 23: Our Next Phase as a Leading Vaccine Biotech Company
Our Next Phase as a Leading Vaccine Biotech Company VLA15 Success Offers Strategic Growth Opportunities Leverage core strengths in vaccine development to deliver greater long-term value Key initiatives: Build scale in R&D pipeline post-VLA15 exit • Strategic in-licensing/M&A to augment clinical-stag
Slide 24: Reaching Further, Where Most Needed
Reaching Further, Where Most Needed Our Vision: a world in which no one dies or suffers from a vaccine-preventable disease ESG Agenda Commercial vaccines with access routes for 100% Protecting Lives people in LMICs1 We develop vaccines for unmet medical needs – focusing on universal access 4 Clinica
Slide 25: Thank you
Thank you Merci Danke Tack valneva